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Reply to T.P. Vassilakopoulos et al
We thank Vassilakopoulos and Johnson1 for having ad-
dressed this important question on the long-term update of
the HD2000 trial.2 Actually, all time-dependent analyses were
conducted with an intention-to-treat (ITT) approach, with the
only exception of the assessment of late events and of second
malignancies that were evaluated per protocol. We also conducted
a per-protocol analysis of patients treated with doxorubicin,
bleomycin, vinblastine, dacarbazine (ABVD, n 5 113); bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone (BEACOPP, n 5 89); and cyclo-
phosphamide, lomustine, vindesine, melphalan, prednisone,
epidoxorubicin, vincristine, procarbazine, vinblastine, and
bleomycin (COPP-EBV-CAD; CEC, n 5 93). Fifteen patients re-
ceived ABVD in place of the randomly assigned arm (BEACOPP,
n 5 9; CEC, n 5 6), and only one patient was randomly as-
signed to receive ABVD, but received CEC. The main reason
for the treatment change was patient request or medical de-
cision. Looking at survival data, the 10-year progression-free
survival rates were 71% (95% CI, 61% to 79%) and 75%
(95% CI, 64% to 83%) for ABVD and BEACOPP, respectively
(P 5 .512). As observed with the ITT analysis, also in the per-
protocol assessment, the proportionality of risk function was
missing: the hazard ratio of BEACOPP against ABVD for
progression-free survival was 0.50 (95% CI, 0.25 to 0.98)
within the ﬁrst 30 months of observation and 2.03 (95% CI,
0.83 to 4.98) after 30 months of follow-up. Again, no difference
among the study arms was observed in the per-protocol anal-
ysis for overall survival (OS): 10-year OS was 85% (95% CI,
76% to 91%) and 84% (95% CI, 73% to 90%) for ABVD and
BEACOPP, respectively.
In conclusion, even if some patients were treated with
ABVD chemotherapy in place of the assigned intensiﬁed re-
gimen after randomization, the per-protocol analysis con-
ﬁrmed the ﬁndings of the ITT analysis, showing better disease
control with BEACOPP compared with ABVD, but higher
frequency of late events with the intensiﬁed treatment, resulting
in the same OS rates. We are looking forward to reading the long-
term results of the other studies that also compared BEACOPP
and ABVD in advanced-stage Hodgkin lymphoma patients.3-5
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